Skip to main content

Table 1 Study participants categories in Indonesia, Kyrgyzstan, Nigeria and all countries combined

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

  Qualitative part Quantitative part
Total Indonesiaa Kyrgyzstan Nigeria Total Indonesiaa Kyrgyzstan Nigeria
Total 188 51 63 74 182 48 63 71
Health care workers 110 28 44 38 110 28 44 38
Laboratory stakeholders 78 23 12 9 72 20 12 9
Programmatic Stakeholders 7 27 7 24
  1. aThe categories laboratory and programmatic stakeholders were merged to ensure anonymity